DelMar Pharmaceuticals, Inc. Announces Scientific Advisory Board Appointments
May 20, 2019 at 03:00 pm IST
Share
DelMar Pharmaceuticals, Inc. announced the appointments of three additional world-class neuro-oncologists to its Scientific Advisory Board (SAB). Dr. David Reardon, clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and a Professor of Medicine at the Harvard Medical School. Dr. Timothy Cloughesy, professor of neurology at the David Geffen School of Medicine at the University of California, Los Angeles and a member of the UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center. Dr. Nicholas Butowski, a neuro-oncologist practicing at UCSF Medical Center in San Francisco, CA, and director of translational research in neuro-oncology and a researcher at the Brain Tumor Center. These new advisors join existing SAB members Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center and Dr. Napoleone Ferrara, world renowned scientist and Distinguished Professor of Pathology and a Distinguished Adjunct Professor of Ophthalmology and Pharmacology at the University of California, San Diego. Dr. Ferrara will serve as Chairman of DelMar's SAB. Dr. David Reardon serves as clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and is a Professor of Medicine at the Harvard Medical School. Dr. Reardon previously served as associate deputy director of the Preston Robert Tisch Brain Tumor Center at Duke University. Dr. Timothy Cloughesyis a professor of neurology at the David Geffen School of Medicine at the University of California, Los Angeles and a member of the UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center. He also serves as the director of UCLA's Neuro-Oncology Program, co-director of the UCLA Brain Tumor Center, and the director of the Henry Singleton Brain Cancer Research Program. Dr. Nicholas Butowski is a neuro-oncologist practicing at UCSF Medical Center in San Francisco, CA.Dr. Butowski serves as director of translational research in neuro-oncology and a researcher at the Brain Tumor Center. He specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders.
Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.